ClinicalTrials.gg
Not yet recruitingNCT06549049Updated Nov 6, 2026

A Transdiagnostic Sleep Health Intervention for Veterans With PTSD

An interventional study of TranS-C for PTSD and Sleep Psychoeducation Control in Stress Disorders, Post-Traumatic and Sleep Initiation and Maintenance Disorders, sponsored by VA Office of Research and Development. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by VA Office of Research and Development · Not applicable, Interventional, and Treatment

Updated Nov 6, 2026Start date movedEligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
182
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 263 studies in Stress Disorders, Post-Traumatic by VA Office of Research and Development — 56 open to participants now, 65 under way, 4 of them phase 3. Stress Disorders, Post-Traumatic · VA Office of Research and Development.

Planned enrollment
49th of 246
182 · median 87
Started
2027
with 13 others
No phase
185 of 263
42 open now
Primary completion
2029-01
later than 36 of 64 live
Registered
232nd of 263
by date

Among the 263 studies in Stress Disorders, Post-Traumatic by VA Office of Research and Development, this one is the 49th largest by planned enrollment of the 246 interventional ones that give a count, is one of 14 that started in 2027, is one of 185 with no phase, reaches primary completion later than 36 of the 64 other live ones, and was the 232nd registered.

Stress Disorders, Post-Traumatic

2,688 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 606 are open to participants now.

Browse Stress Disorders, Post-Traumatic studies →

Open to participants now

56 of the 263 studies in Stress Disorders, Post-Traumatic by VA Office of Research and Development are open now, in 1 country. Recruiting first, the newest first:

51 more — sign in →

By country, each count listing its studies:

All 56 open studies →

Where they have run

Who these studies take

Of the 417 Stress Disorders, Post-Traumatic studies recruiting now, 187 (45%) set no upper age limit and 204 (49%) stop at 75 or younger; 63 take children under 18; 89 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 263 studies in Stress Disorders, Post-Traumatic by VA Office of Research and Development, or all of them as a file.
02

Study summary

Sleep disturbance is a major problem in Veterans with posttraumatic stress disorder (PTSD). This study will test a version of a sleep treatment that's been shown to be effective in the general population, with some changes to tailor it to the needs of Veterans with PTSD and sleep disturbance.

Read the detailed description

Sleep disturbance in military Veterans with PTSD is a complex condition, typically characterized by insomnia and nightmares, and frequently accompanied by comorbid obstructive sleep apnea. Each of these problems are shown to influence the others, contributing to a complex sleep disturbance with profound impacts on daytime functioning and quality of life. A vicious cycle in which nighttime disturbances impact daytime functioning, and vice versa, often ensues. Addressing sleep disturbance in Veterans with PTSD therefore requires a multipronged approach that is tailored to each Veterans' constellation of symptoms and each Veterans' goals for sleep health. The Transdiagnostic sleep and circadian intervention (TranS-C), developed by sleep researchers Allison Harvey, Ph.D. and Daniel Buysse, M.D., involves a patient-centered, module-based, flexibly structured approach that tackles numerous sleep disturbances using evidence-based strategies with the overall goal of improving sleep and improving sleep-related impairments in daytime functioning. It is thus well-suited for tackling sleep disturbances and the associated impairments in social, occupational and overall functioning in Veterans with PTSD. The proposed study is a randomized, controlled clinical trial examining the effectiveness of a modified TranS-C intervention for Veterans with PTSD. The modified approach, referred to as TranS-C for PTSD (TSC-PTSD) elevates the importance of nightmare-focused, apnea-focused, and insomnia-focused modules relative to the standard intervention, incorporates an evidence-based relaxation module, and modifies the nightmare and apnea modules based on strategies used for Veterans in the VA healthcare system. The study will administer TSC-PTSD remotely to Veterans in their homes using a VA-approved video-conferencing platform. The study will recruit male and female U.S. military Veterans aged 18 and above throughout California and compare change in a comprehensive measure of daytime functioning and change in insomnia, nightmare and overall PTSD symptoms in participants randomized to the active intervention TSC-PTSD vs. participants randomized to a sleep psychoeducation control (SPC) intervention. The widely used and validated World Health Organization Disability Assessment Schedule (WHODAS) will serve as the primary outcome measure. The Insomnia Severity Index (ISI) and the Clinician-Administered PTSD Scale (CAPS) will be used to measure secondary outcomes. Eligible participants will have an insomnia diagnosis, a PTSD diagnosis (or moderate symptoms of PTSD in the absence of a full diagnosis), and clinically significant nightmares based on gold-standard clinician-administered interviews. All participants will complete baseline surveys related to daytime functioning and sleep-related symptoms prior to treatment initiation, and will complete these surveys again in week 5, and at the end of treatment. For additional high-resolution data on sleep patterns, all participants will record sleep-related information, including nightmare occurrence and severity, in the morning and at bedtime using a Veteran-tested and user-friendly sleep diary mobile app. Participants will also complete the clinical interview and self-report surveys at 3-month and 6-month follow-up, to assess the durability of treatment effects. The duration of TSC-PTSD may vary between a minimum of 8 and a maximum of 12 sessions and the psychoeducation control protocol will involve 10 sessions. The hypotheses are: 1) subjects randomized to TSC-PTSD will demonstrate greater improvement in WHODAS score relative to SPC from baseline to post-treatment; 2) subjects randomized to TSC-PTSD will demonstrate greater improvements in insomnia, nightmares and PTSD symptoms as demonstrated by improvements in the ISI, CAPS distressing dreams score, and CAPS total score relative to SPC from baseline to post-treatment; and 3) subjects randomized to TSC-PTSD will demonstrate greater sustained improvement in functional and clinical outcomes at 3-month and 6-month follow-up relative to SPC, and improvements in WHODAS score will be mediated by improvements in ISI, nightmares and TranS-C indicators of sleep health in both study groups. Findings in support of the investigators' hypotheses will provide a vital new tool for advancing rehabilitation in U.S. military Veterans with PTSD.

03

Conditions studied

  • Stress Disorders, Post-Traumatic
  • Sleep Initiation and Maintenance Disorders

Keywords

  • Insomnia
  • Posttraumatic stress disorder
  • Veterans
  • Nightmares
  • Psychotherapy
04

Who can participate

The criteria were revised on the registry on Nov 6, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • U.S. Military Veteran engaged in VA primary and/or mental health care
  • Clinician-Administered post-traumatic stress disorder (PTSD) Scale (CAPS-5) PTSD diagnosis; or CAPS 5 score >=25 in the absence of full criteria
  • SCID Insomnia Disorder diagnosis, supported by Insomnia Severity Index (ISI) score >=10
  • CAPS-IV nightmare score >=4
  • Sleep-related functional impairment based on a World Health Organization Disability Assessment Schedule (WHODAS) score >=32
  • Willingness to engage in 8-12 sessions of treatment to address their sleep disturbance

Exclusion criteria

Exclusion Criteria:

  • Current cognitive problems, active psychosis or mania, or other mental/cognitive conditions such as moderate to severe neurodegenerative disease that would render the participant unable to connect to videoconferencing platform, engage in remote psychotherapy, or communicate using the required VA secure email platform
  • No access to reliable internet service connected to a computer, iPad or similar device (telephone not adequate)
  • Inability or unwillingness to use a VA-approved videoconferencing platform and VA secure email
  • Current engagement in a sleep-focused psychotherapy, or plan to start a sleep-focused psychotherapy in the next 3 months. Sleep-focused psychotherapies include, but are not limited to, cognitive behavioral therapy for insomnia (CBT-I), brief behavioral treatment for insomnia (BBT-I), and imagery rehearsal therapy (IRT)
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
182 participants (estimated)

Study arms

  • Experimental
    Arm 1: Experimental

    Participants receiving experimental TSC-PTSD treatment.

    Behavioral: TranS-C for PTSD

  • Active comparator
    Arm 2: Active Control

    Participants receiving sleep psychoeducation control.

    Behavioral: Sleep Psychoeducation Control

Interventions

  • BehavioralTranS-C for PTSD

    The Transdiagnostic sleep and circadian intervention (TranS-C), developed by Allison Harvey, Ph.D. and Daniel Buysse, M.D., involves a patient-centered, module-based, flexibly structured approach that tackles numerous sleep disturbances using evidence-based strategies with the goal of improving sleep and related impairments in daytime functioning. It is thus well-suited for tackling sleep disturbances and the associated impairments in social, occupational and overall functioning in Veterans with PTSD. The proposed study is a randomized, controlled clinical trial examining the effectiveness of a modified TranS-C intervention for Veterans with PTSD. The modified approach, TranS-C for PTSD (TSC-PTSD), elevates the importance of nightmare-focused, apnea-focused, and insomnia-focused modules relative to the standard intervention, incorporates an evidence-based relaxation module, and modifies the nightmare and apnea modules based on strategies used for Veterans in the VA healthcare system.

    Also known as: TSC-PTSD

  • BehavioralSleep Psychoeducation Control

    Participants will receive psychoeducation about sleep.

    Also known as: SPC

06

What researchers measure

Primary outcomes

  1. World Health Organization Disability Assessment Schedule (WHODAS)

    The WHODAS is a validated, comprehensive measure of health-related disability.

    Time frame: Week 0, Week 5, Post-Treatment, 3-Month Follow-Up, 6-Month Follow-Up

Secondary outcomes

  1. Insomnia Severity Index (ISI)

    The ISI will be used to measure change in severity of insomnia symptoms.

    Time frame: Week 0, Week 5, Post-Treatment, 3-Month Follow-Up, 6-Month Follow-Up

  2. Clinician-Administered PTSD Scale for DSM-4 Distressing Dream Score (CAPS-4 Nightmare Item)

    The CAPS-IV Nightmare Item will be used to measure change in nightmare symptoms.

    Time frame: Week 0, Week 5, Post-Treatment, 3-Month Follow-Up, 6-Month Follow-Up

  3. Clinician-Administered PTSD Scale for DSM-5 (CAPS-5)

    The CAPS-5 will be used to measure change in overall PTSD symptoms.

    Time frame: Week 0, Post-Treatment, 3-Month Follow-Up, 6-Month Follow-Up

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Jan 2029, 24 months later.

Of 1,065 non-industry interventional studies with no phase under Stress Disorders, Post-Traumatic, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's planned 24 months is below that.

Counting every sponsor, half of 1,093 studies reached it within 34 months; a quarter within 17 and three quarters within 53.

Start moved twice since we started tracking on Sep 25, 2026: Sep 2026 → Jan 2027, last on Nov 6, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2024
First posted
Aug 12, 2024
StartEst.
Jan 1, 2027was Sep 2026
Primary completionEst.
Jan 31, 2029
CompletionEst.
Jan 31, 2029
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Sep 1, 2026→Jan 1, 2027
moved 2 times, Sep 29, 2026 – Nov 6, 2026
Eligibility
Criteria revised in 2 updates
What changed on Sep 29, 2026
Inclusion criteria
  • EditedClinician-Administered PTSD Scale (CAPS -5) PTSD diagnosis; or CAPS 5 score >=25 in the absence of full criteria
  • EditedSleep-related functional impairment based on a World Health Organization Disability Assessment Schedule (WHODAS) score >=32
What changed on Nov 6, 2026
Inclusion criteria
  • EditedU.S. Military Veteran aged 18 and above engaged in VA primary and/or mental health care
  • EditedClinician-Administered post-traumatic stress disorder (PTSD) Scale (CAPS-5) PTSD diagnosis; or CAPS 5 score >=25 in the absence of full criteria
  • EditedSCID Insomnia Disorder diagnosis, supported by Insomnia Severity Index (ISI) score >=10
Exclusion criteria
  • EditedCurrent engagement in a sleep-focused psychotherapy, or plan to start a sleep-focused psychotherapy in the next 3 months. Sleep-focused psychotherapies include, but are not limited to, cognitive behavioral therapy for insomnia (CBT-I), brief behavioral treatment for insomnia (BBT-I), and imagery rehearsal therapy (IRT)
across 2 updates, Sep 29, 2026 – Nov 6, 2026
Show all 2 updates
  1. Nov 6, 2026
    Start date Oct 15, 2026→Jan 1, 2027
    Eligibility 3 inclusion criteria edited; 1 exclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedU.S. Military Veteran aged 18 and above engaged in VA primary and/or mental health care
    • EditedClinician-Administered post-traumatic stress disorder (PTSD) Scale (CAPS-5) PTSD diagnosis; or CAPS 5 score >=25 in the absence of full criteria
    • EditedSCID Insomnia Disorder diagnosis, supported by Insomnia Severity Index (ISI) score >=10
    Exclusion criteria
    • EditedCurrent engagement in a sleep-focused psychotherapy, or plan to start a sleep-focused psychotherapy in the next 3 months. Sleep-focused psychotherapies include, but are not limited to, cognitive behavioral therapy for insomnia (CBT-I), brief behavioral treatment for insomnia (BBT-I), and imagery rehearsal therapy (IRT)
    + 1 other change: verification date
  2. Sep 29, 2026
    Start date Sep 1, 2026→Oct 15, 2026
    Eligibility 2 inclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • EditedClinician-Administered PTSD Scale (CAPS -5) PTSD diagnosis; or CAPS 5 score >=25 in the absence of full criteria
    • EditedSleep-related functional impairment based on a World Health Organization Disability Assessment Schedule (WHODAS) score >=32
    + 3 other changes: identifiers, verification date and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06549049
Responsible party
Sponsor
First posted
Aug 12, 2024
Start date
Jan 1, 2027 (estimated)
Primary completion
Jan 31, 2029 (estimated)
Completion
Jan 31, 2029 (estimated)
Last update
Nov 6, 2026

Study contacts

Emily J Berg
Contact
emily.berg@va.gov
(415) 900-6016
Anne Richards, MD MPH
principal investigator · San Francisco VA Medical Center, San Francisco, CA

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion